Other Guidelines | Page 49 | European Cystic Fibrosis Society (ECFS)

Outcomes of cystic fibrosis pulmonary exacerbations treated with antibiotics with activity against anaerobic bacteria

Defining key outcomes to evaluate performance of newborn screening programmes for cystic fibrosis

Amphotericin B induces epithelial voltage responses in people with cystic fibrosis

Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020.

The role of the “PTM-CODE” in restoring F50del-CFTR functionality

Trends in the use of healthcare resources over time and the associated costs for people with cystic fibrosis?

Optimising equity of access: how should we allocate slots to the most competitive trials in Cystic Fibrosis (CF)?

Emergence and impact of oprD mutations in Pseudomonas aeruginosa strains in cystic fibrosis

Peripheral lung effect of elexacaftor/tezacaftor/ivacaftor in adult cystic fibrosis

Nasal high-flow therapy as an adjunct to exercise in patients with cystic fibrosis: A pilot feasibility trial

first
previous
…
45
46
47
48
49
50
51
52
53
…
next
last